Unmet medical needs in Parkinson's disease.
Neurology
; 62(1 Suppl 1): S1-8, 2004 Jan 13.
Article
em En
| MEDLINE
| ID: mdl-14718675
ABSTRACT
Levodopa, introduced in the late 1960s, was the first highly effective drug for the symptomatic treatment of Parkinson's disease (PD) and remains the mainstay of pharmacologic treatment. However, long-term treatment has important limitations. The disease continues to progress despite treatment with levodopa, and a neuroprotective therapy is urgently required. In addition, motor complications associated with chronic levodopa therapy are an important source of disability. Treatment of these complications forms a major focus of modern PD management, and it is in this area that recent advances in our knowledge offer the best opportunity for therapeutic gain. In the search for improved therapies, suitable outcome measures to better assess overall disability in PD and disease progression are essential.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Levodopa
/
Discinesia Induzida por Medicamentos
/
Antiparkinsonianos
Limite:
Humans
Idioma:
En
Revista:
Neurology
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Estados Unidos
País de publicação:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA